Financially stable C4 Therapeutics (CCCC) is worth watching for patient investors, but current lack of definitive data poses ...

Cassava Sciences (NASDAQ:SAVA) reported better-than-expected earnings with its Q3 2024 financials on Thursday and reaffirmed ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Emmanuel Macron and Donald Trump shared a "wish to work together for the return of peace and stability" faced with "major ongoing international crises", the French president's office said on Wednesday ...

Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder ...

U.S. Defense Secretary Lloyd Austin called former Israeli Defense Minister Yoav Gallant on Thursday, just two days after he ...

The prime minister has taken to talking about “two sides of the same coin” a lot recently – it’s possible to go for growth while doing so in a way that’s good for workers, is his point.

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...